Overview

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Phase:

N/A

Details

Lead Sponsor:

King Faisal Specialist Hospital & Research Center

Treatments:

Imatinib Mesylate